<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01017666</url>
  </required_header>
  <id_info>
    <org_study_id>204HV103</org_study_id>
    <secondary_id>EUDRA CT 2009-014259-60</secondary_id>
    <nct_id>NCT01017666</nct_id>
  </id_info>
  <brief_title>BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of BIIB014 on the Pharmacokinetics of Rosiglitazone, Warfarin, and Midazolam in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand whether BIIB014 has potential to affect how
      certain drugs are broken down by the body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of rosiglitazone (Cohort 1), midazolam &amp; metabolites and s-warfarin (Cohort 2) during steady state exposure to BIIB014 or placebo</measure>
    <time_frame>24 hours (Cohort 1); 144 hours (Cohort 2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Duration of subject participation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rosiglitazone 8mg PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam 2mg PO, Warfarin 25mg PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB014</intervention_name>
    <description>BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d</description>
    <arm_group_label>Midazolam 2mg PO, Warfarin 25mg PO</arm_group_label>
    <arm_group_label>Rosiglitazone 8mg PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d</description>
    <arm_group_label>Midazolam 2mg PO, Warfarin 25mg PO</arm_group_label>
    <arm_group_label>Rosiglitazone 8mg PO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects

          -  Between the ages of 18 and 45, inclusive.

          -  Must have a body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive

        Exclusion Criteria:

          -  Clinically significant abnormalities (as determined by the Investigator)

          -  Other unspecified reason that would make the subject unsuitable for enrollment (as
             determined by the Investigator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>InCROM Clinical Research Unit</name>
      <address>
        <city>London</city>
        <zip>E14NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2009</study_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clinical Trial Manager</name_title>
    <organization>Biogen Idec Ltd</organization>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

